Form 4: Ingevity Director Benjamin Wright Receives Stock Grant

Director Benjamin G. Wright acquired 1,904 deferred stock units in lieu of his annual restricted stock unit grant.

Summary

• Director Benjamin G. Wright was granted 1,904 deferred stock units (DSUs) on April 30, 2026.
• The grant was made in lieu of the standard annual non-employee director restricted stock unit grant.
• Following this transaction, the director's total beneficial ownership of common stock is 11,948 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• The director has increased his equity stake in the company, aligning his interests with shareholders.

Negatives

• None identified.

Risks

• The value of the deferred stock units is subject to the future market performance of Ingevity Corporation common stock.

Future Outlook

The DSUs will vest on April 30, 2027, and will settle into common stock upon the director's termination of board service.

Industry Context

StockSavvy.ai notes that director equity grants in lieu of cash or standard RSU compensation are common governance practices designed to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of deferred stock units for director compensation is consistent with standard corporate governance practices for mid-cap industrial companies.
• The structure follows typical equity incentive plans seen in companies like WestRock or Eastman Chemical.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from increased director alignment with long-term stock performance.

Next Steps

• Vesting of the 1,904 deferred stock units on April 30, 2027.

Key Dates

Keywords

Ingevity, NGVT, Form 4, Director Compensation, Insider Transaction, Deferred Stock Units